icosapent ethyl
Selected indexed studies
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. (N Engl J Med, 2019) [PMID:30415628]
- Icosapent ethyl: From the REDUCE-IT trial to clinical practice. (Clin Investig Arterioscler, 2025) [PMID:40467382]
- Icosapent ethyl: scientific and legal controversies. (Open Heart, 2021) [PMID:33888593]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. (2019) pubmed
- Icosapent ethyl: From the REDUCE-IT trial to clinical practice. (2025) pubmed
- Icosapent ethyl: scientific and legal controversies. (2021) pubmed
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. (2020) pubmed
- Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. (2024) pubmed
- Icosapent Ethyl: Niche Drug or for the Masses? (2020) pubmed
- Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. (2022) pubmed
- Emphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review. (2022) pubmed
- Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date. (2020) pubmed
- Cardiovascular risk reduction with icosapent ethyl. (2019) pubmed